Biogen Strikes Deal for Orelabrutinib, Now in Phase 2 Trial

Biogen Strikes Deal for Orelabrutinib, Now in Phase 2 Trial

299310

Biogen Strikes Deal for Orelabrutinib, Now in Phase 2 Trial

Biogen has signed a deal with InnoCare Pharma to acquire global commercialization and licensing rights to orelabrutinib, an experimental oral BTK inhibitor (BTKi) now being tested in people with relapsing-remitting multiple sclerosis (RRMS) in a Phase 2 clinical trial. Under the terms of the agreement, Biogen will have exclusive rights to the therapy in the field of MS worldwide and of certain autoimmune diseases outside of China (including Hong Kong, Macau, and Taiwan), while InnoCare will…

You must be logged in to read/download the full post.